Use of Bisphosphonates in Patients with Metastatic Bone Disease

James R. Berenson, Allan Lipton

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Since these agents had demonstrated efficacy in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies were initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases. Recent, large, randomized, double-blind studies have shown the efficacy of these agents in reducing skeletal complications in patients with bone metastases from both breast cancer and multiple myeloma.

Original languageEnglish (US)
Pages (from-to)1573-1579
Number of pages7
Issue number11
StatePublished - 1998

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Use of Bisphosphonates in Patients with Metastatic Bone Disease'. Together they form a unique fingerprint.

Cite this